Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
CLINSQUARE: CLINICAL RESEARCH COURSES
Monday, March 24, 2025
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Facebook
Twitter
CLINSQUARE: Clinical Rsearch Courses by LIFEPRONOW
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
Tags
Jakavi
Tag:
Jakavi
Latest Pharma-News
Novartis receives EC approval for Jakavi® for acute and chronic graft-versus-host disease
admin
-
May 13, 2022
0
Latest Pharma-News
Novartis announces positive Phase III REACH3 data for Jakavi in chronic GvHD
admin
-
July 15, 2021
0
Latest Pharma-News
Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease
admin
-
July 24, 2020
0
Latest Pharma-News
Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
admin
-
April 23, 2020
0
Latest Pharma-News
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
admin
-
April 8, 2020
0
- Advertisment -
Most Read
FDA Alerts Patients of Potential to Miss Critical Safety Alerts Due to Phone Settings When Using Smartphone-Compatible Diabetes Devices
February 10, 2025
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
February 3, 2025
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
February 3, 2025
Johnson & Johnson investigational therapy was recently granted U.S. FDA Priority Review for the treatment of gMG
January 24, 2025